Fig. 2: Meta-analysis: predictive biomarkers in PARP inhibitor efficacy.

a BRCA1/2 pathogenic variants and tumour HRD as predictors of PARP Inhibitor efficacy across treatment settings. b BRCA1/2 pathogenic variants and HRD in frontline treatment. c BRCA1/2 pathogenic variants and HRD in recurrent treatment.